Cardiff Oncology Sees Unusually Large Options Volume (NASDAQ:CRDF)

Cardiff Oncology, Inc. (NASDAQ:CRDF) was the recipient of unusually large options trading activity on Tuesday. Stock investors bought 2,705 call options on the company. This is an increase of approximately 288% compared to the typical daily volume of 698 call options.

Cardiff Oncology Price Performance

Shares of CRDF traded down $1.01 during midday trading on Tuesday, hitting $1.93. The stock had a trading volume of 6,047,238 shares, compared to its average volume of 1,045,943. The firm has a market cap of $129.94 million, a price-to-earnings ratio of -2.44 and a beta of 1.40. The company has a 50 day simple moving average of $2.61 and a two-hundred day simple moving average of $2.53. Cardiff Oncology has a twelve month low of $1.85 and a twelve month high of $4.99.

Cardiff Oncology (NASDAQ:CRDF) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.03. Cardiff Oncology had a negative net margin of 10,064.27% and a negative return on equity of 77.21%. The company had revenue of $0.12 million for the quarter, compared to the consensus estimate of $0.12 million. Analysts forecast that Cardiff Oncology will post -0.99 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Capital Advisors Wealth Management LLC purchased a new stake in shares of Cardiff Oncology in the fourth quarter valued at about $30,000. Jeppson Wealth Management LLC purchased a new position in Cardiff Oncology in the third quarter worth $25,000. Brooklyn Investment Group bought a new position in Cardiff Oncology in the 3rd quarter valued at $26,000. Integrity Alliance LLC. purchased a new stake in shares of Cardiff Oncology during the 2nd quarter valued at $41,000. Finally, Engineers Gate Manager LP purchased a new stake in shares of Cardiff Oncology during the 2nd quarter valued at $43,000. Institutional investors own 16.29% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cardiff Oncology in a research note on Wednesday, January 21st. Noble Financial began coverage on Cardiff Oncology in a report on Monday, January 5th. They issued an “outperform” rating and a $12.00 price target for the company. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $11.13.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.